Among the proteins implicated in age‑related neurodegeneration, TDP‑43 has taken on growing importance: its misfolding and mislocalization are now linked to frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and are estimated to be present in more than half of Alzheimer’s cases. Faster cognitive decline, greater brain atrophy, and worsening memory loss are all associated with TDP-43.

Now, researchers at the University of California, San Diego (UCSD), are testing a gene‑therapy strategy designed not to remove TDP‑43, but to help neurons withstand its toxicity. In a study published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the team reports that systemic delivery of a gene called SynCav1 to brain cells protected cognition and preserved neuronal structure in a mouse model of TDP‑43 proteinopathy. The study is titled, “Systemic delivery of synapsin-promoted caveolin-1 overexpression ameliorates pathological TDP-43–induced cognitive decline and neurodegenerative changes.”

The approach centers on caveolin‑1, a scaffolding protein that organizes membrane signaling domains and supports neuronal resilience. The researchers packaged SynCav1 into a modified AAV vector capable of crossing the blood–brain barrier—a notable departure from many CNS gene therapies that require direct injections into brain tissue. Once delivered, SynCav1 boosted caveolin‑1 expression across the brain and spinal cord.

“Many therapies for neurodegenerative disease focus on removing toxic proteins, but neurons are also losing their ability to cope with that stress,” said senior author Brian Head, PhD, professor of anesthesiology at UCSD School of Medicine and research career scientist at the Veterans Affairs San Diego Healthcare System. “Our findings suggest that strengthening the neuron’s resilience itself may be a powerful therapeutic strategy, even when toxic proteins are already present.”

In treated TDP-43^A315T mouse models, SynCav1 preserved learning and memory deficits, behavioral domains typically impaired by TDP‑43 pathology. The therapy also reduced levels of pathological TDP‑43 in the cortex and hippocampus. At the subcellular level, SynCav1 protected mitochondrial structure, stabilized membrane lipid rafts (MLR), and maintained MLR-associated GluN2A receptor expression, which is essential for excitatory synaptic signaling.

The mechanistic insight emerged from a striking observation: in diseased mice, TDP‑43 mislocalized to membrane lipid rafts, disrupting signaling hubs and degrading synaptic ultrastructure. “We found that TDP‑43 is not only accumulating in the wrong subcellular compartments…but also disrupts cellular processes that are essential for neurons to communicate with one another,” said co‑corresponding author Shanshan Wang, MD, PhD, assistant professor of anesthesiology at UCSD School of Medicine. “SynCav1 appears to help preserve this molecular machinery and subcellular localization.”

Electron microscopy revealed that SynCav1 also mitigated mitochondrial hyper‑fragmentation and excessive fission signaling. Axonal myelin integrity was preserved as well, as reported in the study.

“What is especially exciting is that we saw protection across multiple levels—behavior, synapses, axons, membrane signaling, and mitochondrial structure,” Head added. “That kind of broad neuroprotection is exactly what is needed in complex disorders like TDP‑43‑related dementias.”

The authors emphasize that the work is preclinical, but the results support SynCav1 as a neuron‑centric therapeutic candidate that could be applicable across multiple TDP‑43‑linked diseases.

Brian P. Head, PhD, holds equity in and serves as a non‑paid scientific advisory board member for Eikonoklastes Therapeutics. Other authors reported no competing interests.

The post Gene Therapy Shows Promise Against TDP‑43 Neurodegeneration in Mice appeared first on GEN – Genetic Engineering and Biotechnology News.